TGTX Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of 4.19% compared to TG Therapeutics's net margin of -48.92%. TG Therapeutics's return on equity of 19.78% beat Axsome Therapeutics's return on equity of -309.19%.

TG Therapeutics has a consensus price target of $43.50, signalling upside risk potential of 30.36%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.35 which suggests that it could grow by 66.89%. Given that Axsome Therapeutics has higher upside potential than TG Therapeutics, analysts believe Axsome Therapeutics is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. TG Therapeutics's net income of $5.1M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, TG Therapeutics's price-to-earnings ratio is 139.04x while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 13.89x versus 11.81x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Editas Medicine has a net margin of 4.19% compared to TG Therapeutics's net margin of -1633.49%. TG Therapeutics's return on equity of 19.78% beat Editas Medicine's return on equity of -139.77%.

TG Therapeutics has a consensus price target of $43.50, signalling upside risk potential of 30.36%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 125%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than Editas Medicine quarterly revenues of $4.7M. TG Therapeutics's net income of $5.1M is higher than Editas Medicine's net income of -$76.1M. Notably, TG Therapeutics's price-to-earnings ratio is 139.04x while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 13.89x versus 3.46x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of 4.19% compared to TG Therapeutics's net margin of -1036.46%. TG Therapeutics's return on equity of 19.78% beat Ocugen's return on equity of -215.5%.

TG Therapeutics has a consensus price target of $43.50, signalling upside risk potential of 30.36%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 825.27%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than Ocugen quarterly revenues of $1.5M. TG Therapeutics's net income of $5.1M is higher than Ocugen's net income of -$15.4M. Notably, TG Therapeutics's price-to-earnings ratio is 139.04x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 13.89x versus 43.44x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of 4.19% compared to TG Therapeutics's net margin of -598.74%. TG Therapeutics's return on equity of 19.78% beat Ocular Therapeutix's return on equity of -56.05%.

TG Therapeutics has a consensus price target of $43.50, signalling upside risk potential of 30.36%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 150%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. TG Therapeutics's net income of $5.1M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, TG Therapeutics's price-to-earnings ratio is 139.04x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 13.89x versus 19.67x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.